Journal article

Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting

Louise Kostos, Wei Hong, Belinda Lee, Ben Tran, Sheau Wen Lok, Angelyn Anton, Grace Gard, Yat Hang To, Vanessa Wong, Jeremy Shapiro, Rachel Wong, Shirley Wong, Richard de Boer, Peter Gibbs

INTERNATIONAL JOURNAL OF CANCER | WILEY | Published : 2021

Abstract

Clinical trials have strict eligibility criteria, potentially limiting external validity. However, while often discussed this has seldom been explored, particularly across cancer types and at variable time frames posttrial completion. We examined comprehensive registry data (January 2014 to June 2019) for standard first-line treatments for metastatic colorectal cancer (CRC), advanced pancreatic cancer (PC), metastatic HER2-amplified breast cancer (BC) and castrate-resistant prostate cancer (CaP). Registry patient characteristics and outcomes were compared to the practice-changing trial. Registry patients were older than the matched trial cohort by a median of 2-6 years (all P = <.01) for the..

View full abstract